ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy.
 PMID: 11170234       2001       Journal of clinical laboratory analysis
Abstract: The most frequent RT mutations were T215Y/F, M41L, and M184V (41.9, 40.8, and 40.8%, respectively), while L63P, L10R/V, and A71V/T (58, 41.9, and 34.4%, respectively) were the most represented protease substitutions.


  Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.
 PMID: 11170982       2001       The Journal of infectious diseases
Abstract: Previous zidovudine or lamivudine use and presence at baseline of the M184V reverse-transcriptase mutation did not impact virologic response.


  Prevalence and conditions of selection of E44D/A and V118I human immunodeficiency virus type 1 reverse transcriptase mutations in clinical practice.
 PMID: 11181387       2001       Antimicrobial agents and chemotherapy
Abstract: Recently, it has been shown that a new mutational pattern (the E44D/A and/or V118I mutation) confers moderate phenotypic lamivudine resistance in the absence of the M184V mutation.
Abstract: These mutations are more stable than the M184V substitution during antiretroviral treatment interruptions.
Abstract: They are always associated with zidovudine resistance-associated mutations, even in the absence of M184V.


  Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid.
 PMID: 11242181       2001       Journal of acquired immune deficiency syndromes (1999)
Abstract: A median infectious dose (IC50) increase of fourfold for any drug was found in 7 patients, and in 2 was > tenfold for zidovudine (genotype M41L + T215Y) and lamivudine (genotype M184V), respectively.


  International perspectives on antiretroviral resistance. Nucleoside reverse transcriptase inhibitor resistance.
 PMID: 11264998       2001       Journal of acquired immune deficiency syndromes (1999)
Abstract: Other features of NRTI resistance, such as the theoretic reversal of zidovudine resistance associated with the M184V mutation or the powerful influence of the Q151M multiple-drug resistance mutation, have revealed the unpredictable nature of HIV resistance and how much we still need to learn.


  Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1.
 PMID: 11311097       2001       JAMA
Abstract: The M184V lamivudine resistance mutation was detected at 6 weeks after delivery in specimens from 52 of 132 women.


  HIV protease and reverse transcriptase variation and therapy outcome in antiretroviral-naive individuals from a large North American cohort.
 PMID: 11316997       2001       AIDS (London, England)
Abstract: However, the data suggest that some individuals (harboring a M184V mutation in RT or a V82I in protease) may have benefited from pre-therapy resistance tests.


  HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir.
 PMID: 11371689       2001       AIDS (London, England)
Abstract: CONCLUSIONS: Substantial decreases in plasma and CSF HIV-1 RNA following addition of ABC were not precluded by baseline HIV-1 NRTI-associated mutations, including the M184V mutation, but non-responders commonly harbored multiple ZDV/d4T-associated mutations.
Abstract: RESULTS: Sixty out of sixty-seven subjects with baseline plasma HIV-RT sequence data harbored virus with > or = 1 NRTI-associated mutations; 50 out of 67 had the M184V mutation.


  Resistance to antiretroviral therapy among patients in Uganda.
 PMID: 11391172       2001       Journal of acquired immune deficiency syndromes (1999)
Abstract: Among 8 patients taking lamivudine, phenotypic resistance was found for 9 (90%) of 10 specimens and was associated with an M184V mutation in all nine cases.


  Virological response in multidrug-experienced HIV-1-infected subjects failing highly active combination regimens after shifting from lamivudine to didanosine.
 PMID: 11417760       2001       Antiviral therapy
Abstract: At the time of the regimen shift, all the subjects exhibited a high-level phenotypic resistance to both zidovudine and lamivudine with changes at codons 70-219 in 100% of cases, at codon 215 in 13 of 16 patients, and the M184V substitution in 13/16 patients.
Abstract: These findings suggest the possibility of achieving a viral load response to didanosine-containing regimens in patients with reverse transcriptase (RT) M184V mutations who were previously treated with this drug and its possible use in salvage combinations.



Browser Board

 Co-occurred Entities




   Filtrator